文献速递系统性红斑狼疮

系统性红斑狼疮糖皮质激素基因特征及I型干扰素的影响:横断面与体外研究

Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study.
PubMed 文献 · Lancet Rheumatol · 2021-03-30

本研究在三个SLE队列中评估糖皮质激素调控基因作为糖皮质激素暴露生物标志物的潜力,并探讨其与I型干扰素的相互作用。

要点

  • I型干扰素基因特征高表达患者糖皮质激素基因特征表达降低。
  • I型干扰素抑制糖皮质激素诱导基因,可能参与SLE糖皮质激素抵抗。

核心结论

  • 糖皮质激素基因特征与糖皮质激素剂量相关,但I型干扰素对糖皮质激素诱导基因的显著影响可能限制其在SLE中的应用。
  • I型干扰素调控基因对糖皮质激素不敏感,支持I型干扰素在SLE糖皮质激素抵抗中起作用的概念。

研究设计与样本

  • 横断面研究,纳入符合美国风湿病学会SLE标准的成人患者,来自三个队列:澳大利亚墨尔本某三级医院本地队列、公共数据集GSE49454和GSE88884。
  • 体外RNA测序使用健康供者白细胞,分别经地塞米松、I型干扰素或两者联合处理。

主要发现

  • 在本地SLE队列(n=18)和公共数据集GSE49454(n=62)中,五个基因与糖皮质激素剂量相关,组合构成糖皮质激素基因特征。
  • 糖皮质激素剂量对I型干扰素调控基因表达无影响。
  • 匹配糖皮质激素剂量后,高I型干扰素基因特征患者相比低I型干扰素基因特征患者,糖皮质激素基因特征表达降低。

关键数值与推荐

  • 本地SLE队列n=18,GSE49454队列n=62,GSE88884队列n=1756。

临床怎么用

  • 糖皮质激素基因特征可能作为糖皮质激素暴露的生物标志物,但需考虑I型干扰素水平的影响。
  • 在SLE患者中,高I型干扰素可能削弱糖皮质激素诱导基因表达,提示糖皮质激素抵抗机制。

局限性

  • I型干扰素对糖皮质激素诱导基因的显著影响可能限制该特征在SLE中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucocorticoids, used as a therapy in systemic lupus erythematosus (SLE), interact with the cytoplasmic glucocorticoid receptor to modulate gene transcription. Minimising the use of glucocorticoids is a goal in SLE; however, pharmacological measures to support clinical guidelines are scarce. We evaluated glucocorticoid-regulated genes for their potential use as biomarkers of glucocorticoid exposure in SLE. We examined interactions between changes in gene expression that are induced by glucocorticoids and type I interferon. METHODS: Genes regulated by glucocorticoids and type I interferon were analysed in relation to glucocorticoid exposure in adult patients meeting the American College of Rheumatology criteria for SLE from three cross-sectional cohorts: a local cohort from a tertiary hospital in Melbourne, VIC, Australia, and two public datasets (GSE49454, Hospital de la Conception, Marseille, France, and GSE88884, patients enrolled in a large, multicentre clinical trial). RNA sequencing was done using RNA from healthy donor leucocytes treated with the glucocorticoid dexamethasone, or type I interferon, or both. FINDINGS: Glucocorticoid-regulated genes were analysed in a local SLE cohort (n=18) and public dataset GSE49454 (n=62). Five genes correlated with glucocorticoid dose in both cohorts and were combined to make a glucocorticoid gene signature. Validity of the glucocorticoid gene signature was tested in the public dataset GSE88884 (n=1756). A dose-dependent association was observed with glucocorticoid dose (p<0·0001), and the glucocorticoid gene signature had moderate ability to identify patients taking high-dose glucocorticoid (area under the curve [AUC]=0·77) although was less discriminatory when including all doses (AUC=0·69). We saw no effect of glucocorticoid dose on type I interferon -regulated gene expression. Patients with a high type I interferon gene signature had reduced glucocorticoid gene signature expression compared with patients with a low type I interferon gene signature matched for glucocorticoid dose, suggesting type I interferon inhibits glucocorticoid-stimulated gene expression. In RNA sequencing experiments, type I interferon impaired the expression of glucocorticoid-induced genes, whereas dexamethasone had minimal effect on the expression of type I interferon-stimulated genes. We identified genes regulated by dexamethasone but not affected by type I interferon; combined signatures using these genes also showed moderate ability to distinguish patients taking glucocorticoids. INTERPRETATION: A gene signature for glucocorticoid exposure was identified, but the substantial effect of type I interferon on glucocorticoid-induced genes might limit its application in SLE. These data confirm the insensitivity of type I interferon-regulated genes to glucocorticoids, and together support the concept that type I interferon has a role in glucocorticoid resistance in SLE. FUNDING: Lupus Research Alliance and Australian National Health and Medical Research Council.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Northcott M, Gearing LJ, Nim HT, et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. Lancet Rheumatol. 2021. PMID: 38279391. doi:10.1016/S2665-9913(21)00006-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。